Company Overview
Palisade Bio, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing oral phosphodiesterase-4 inhibitor prodrugs engineered for targeted delivery specifically to the terminal ileum and colon within the United States. The company functions within the Healthcare sector and the Biotechnology industry, a classification that signifies its focus on the early stages of drug development rather than commercialized product sales. As of the latest reported data, the firm holds a market capitalization of $332.17M, while specific annual revenue figures are not currently disclosed in the available financial records, and the employee count is listed as N/A. These valuation metrics indicate that the company is a mid-sized entity in the biotechnology landscape, where market capitalization often reflects the potential value of pipeline assets rather than established revenue streams, suggesting a position heavily dependent on future clinical milestones to drive market perception.
Financial Health
The company reports Net Income (TTM) of $-16,781,000 and EBITDA of $-18,053,000, while Revenue (TTM) is not available in the provided data. The substantial gap between reported revenue and net income, combined with significant operating losses, reveals a cost structure dominated by research and development expenditures typical of clinical-stage firms, where costs are incurred to advance drug candidates through trial phases before any commercial revenue is recognized. Free Cash Flow stands at $-5,923,250, indicating that the company is currently burning cash to fund its operations and clinical trials, which limits immediate financial flexibility but is a common characteristic of companies in the developmental phase of product candidates. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that indicates the company has not yet generated sufficient commercial sales to establish positive margins, as these are calculated based on negligible or non-existent revenue relative to the massive underlying costs. Regarding capital structure, the company holds Cash of $133.38M against Debt of $71,000, resulting in a Debt to Equity ratio of 0.06. This disparity demonstrates a highly conservative balance sheet with minimal leverage, providing a robust runway to fund operations without the pressure of significant interest payments. The Current Ratio is listed at 28.95, a metric that indicates an exceptionally strong short-term liquidity position, suggesting the company possesses ample current assets to cover its short-term liabilities many times over. Furthermore, the Return on Equity is -24.5% and the Return on Assets is -15.5%, metrics that reveal that management is currently generating negative returns on the capital invested, a standard outcome for early-stage biotechnology companies that have not yet reached commercialization or profitability.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to the lack of positive earnings, while the Forward P/E is reported as -7.45. The negative forward P/E implies that analysts are pricing in expectations of future earnings recovery or that the valuation is currently based on non-traditional metrics due to the absence of current profitability. The Price to Book ratio is 2.47, which indicates that the market is valuing the company at a premium of 147% over its book value, a common occurrence in biotechnology where intangible assets like intellectual property and pipeline potential are not fully captured on the balance sheet. The Price to Sales ratio is N/A because the company has not generated sufficient commercial revenue to establish a meaningful sales multiple, and the EV/EBITDA stands at -10.99, suggesting that the enterprise value is heavily influenced by the cash position rather than earnings power. The 52-week high is $2.64 and the 52-week low is $0.53; without a specific current price provided in the facts, the valuation context relies on the wide trading range which reflects the high volatility often associated with clinical-stage assets. The Beta is 1.55, a value that indicates the stock's price volatility is 55% higher than that of the broader market, signaling that investor sentiment toward the company's specific clinical pipeline developments will drive price swings more aggressively than general market movements.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company is in a pre-revenue or early revenue stage where historical year-over-year growth rates cannot be calculated from available financial statements. Since the growth rates are unavailable, it is not possible to determine if earnings are growing faster or slower than revenue, as the company has not yet established a consistent commercial sales track record. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the company reinvests all available cash flow into its research and development efforts rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by a total reliance on capital appreciation driven by clinical trial successes and future commercialization potential, rather than current income generation or dividend distributions.